On the 26 October 2011, The Lancet Infectious Diseases published a systematic review and a meta-analysis, combining the results of several studies undertaken on influenza vaccine effectiveness.
This is an authoritative independent evidence-based review and meta-analysis of the efficacy and effectiveness of influenza vaccines. It confines itself to trials and observational studies where diagnostic tests confirmed influenza infection as the end point.
The one-day workshop was the 2nd of a series of workshops in support to the Council Recommendation of December 2009 that encourages EU and EEA Member States to adopt and implement action plans or policies to improve seasonal influenza vaccination coverage.
The 2011 seasonal influenza immunisation campaigns have started across Europe. As in previous years ECDC is marking the start of the 2011-12 surveillance season in Week 40 with the publication of regular weekly updates of the main epidemiological and virological developments in the Weekly Influenza Surveillance Overview (WISO).
EMA recommends restricting use in persons under 20 years of age Pandemrix to be used only in the absence of seasonal trivalent influenza vaccines, following link to very rare cases of narcolepsy in young people. Overall benefit-risk remains positive.
On 21 July 2011 the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued its opinion on the review of Pandemrix® and reports on narcolepsy. The CHMP recommended that in persons under 20 years of age Pandemrix® may only be used if the recommended seasonal trivalent influenza vaccine is not available and if immunisation against H1N1 is still needed (e.g. in persons at risk of the complications of infection).
ECDC has previously summarised information concerning the appearance of narcolepsy following the use of a specific pandemic vaccine (Pandemrix®) in children and adolescents in three European Countries.
The European Medicines Agency (EMA) was key in the Europe during the 2009 pandemic concerning the authorisation and the benefit – risk assessment of the novel pandemic vaccines.